Important Update: We are pleased to announce significant enhancements to our FHIR Terminology Server, offering more seamless and standards-based access to terminology content for healthcare data exchange. Discover the new features and upcoming changes to our Terminology Gateway.
Learn More >
We'd like to hear your thoughts about the naming of biologic drugs including biosimilars. This questionnaire consists of 5 questions.
Access the Consultation and Questionnaire link below: lnkd.in/dZFZXc9
Your responses before February 9th, to this consultation questionnaire will help to inform the development of Health Canada's naming policy to distinguish among biologic drugs that share the same non-proprietary name.
Improving the quality of patient care through the effective sharing of clinical information among health care organizations, clinicians and their patients.
Print
Email
Naming of Biologics: We want to hear from you!
Twitter